Marty Coyne
Marty Coyne has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Chris Franzese
Matchstick LLC, Boonton, NJ, USA
6 shared publications Amy Rinaldi
Matchstick LLC, Boonton, NJUSA
2 shared publications- Colby Thomas
Matchstick, Boonton, NJ, USA
2 shared publications - Dimos Katsaros
Matchstick LLC, Boonton, NJ, USA
2 shared publications Erika Bajars
Matchstick LLC, Boonton, NJUSA
2 shared publications- James Hawthorne
Matchstick LLC, Boonton, NJ, USA
2 shared publications
Latest Publications
- Open Access
- 9 November 2026
- Published by Taylor & Francis in Expert Opinion on Drug Delivery
- p. 1-34
Current practices, challenges, and future directions in subcutaneous oncology monoclonal antibody delivery: a qualitative study
1. The transition from intravenous (IV) to subcutaneous (SC) delivery of biotherapeutics, such as monoclonal antibodies (mAbs), is prominent for a variety of reasons. Perhaps the most important is ...
- 9 November 2026
- Published by Taylor & Francis in Expert Opinion on Drug Delivery
- p. 1-34
Open AccessCurrent practices, challenges, and future directions in subcutaneous oncology monoclonal antibody delivery: a qualitative study
1. The transition from intravenous (IV) to subcutaneous (SC) delivery of biotherapeutics, such as monoclonal antibodies (mAbs), is prominent for a variety of reasons. Perhaps the most important is ...
- Open Access
- 1 August 2025
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. ume 19, 2459-2491
Patient Experience and Improvement Opportunities in Self-Administered, Large-Volume Subcutaneous Infusions at Home
Purpose: Subcutaneous (SC) administration is largely established as the preferred route to deliver biotherapeutics. Although the majority of approved SC products are limited to dose volumes ≤ 2.25 mL, there has been increasing industry focus on large-volume SC (LVSC) development. To date, however, there are few LVSC biotherapeutics available for self-administration, and subcutaneous immunoglobulin (SCIg) remains the most established example. As a result, there is limited published literature on real-world practices with LVSC therapies to inform user needs and preferences for delivery device design attributes. Patients and Methods: This was a remote ethnography study of patients self-administering SCIg at home for treatment of primary immunodeficiency diseases (PIDD). Participants passively video recorded their preparation and infusion processes, took photos, and provided open responses to illustrate their overall experiences with their disease, infusions, and delivery devices. Qualitative data were compiled, analyzed, and grouped into themes and subthemes that represented participant responses and sentiments. Results: A total of 11 patients completed the remote study, all of whom were diagnosed with PIDD. Enrolled participants were currently infusing SCIg with one of five delivery devices and most also had previous experience with another delivery device. Emerging themes included universal preference for SC administration and pain points associated with managing medication/supply orders, storing medications/supplies, troubleshooting device issues, performing burdensome medication preparations, priming tubing/needles, inserting/securing needles, programming devices, adapting to device volume constraints, and loading reservoirs or tubing into delivery devices. Conclusion: Although patients prefer LVSC administration at home compared to the alternatives, the current SCIg use process presents a variety of challenges. While not all of these factors will apply to every LVSC scenario, these insights, along with their corresponding implications for device design, provide a framework to inform user needs for LVSC self-administration, anticipate obstacles during development of new LVSC therapies, and improve existing delivery devices.
- 1 August 2025
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. ume 19, 2459-2491
Open AccessPatient Experience and Improvement Opportunities in Self-Administered, Large-Volume Subcutaneous Infusions at Home
Purpose: Subcutaneous (SC) administration is largely established as the preferred route to deliver biotherapeutics. Although the majority of approved SC products are limited to dose volumes ≤ 2.25 mL, there has been increasing industry focus on large-volume SC (LVSC) development. To date, however, there are few LVSC biotherapeutics available for self-administration, and subcutaneous immunoglobulin (SCIg) remains the most established example. As a result, there is limited published literature on real-world practices with LVSC therapies to inform user needs and preferences for delivery device design attributes. Patients and Methods: This was a remote ethnography study of patients self-administering SCIg at home for treatment of primary immunodeficiency diseases (PIDD). Participants passively video recorded their preparation and infusion processes, took photos, and provided open responses to illustrate their overall experiences with their disease, infusions, and delivery devices. Qualitative data were compiled, analyzed, and grouped into themes and subthemes that represented participant responses and sentiments. Results: A total of 11 patients completed the remote study, all of whom were diagnosed with PIDD. Enrolled participants were currently infusing SCIg with one of five delivery devices and most also had previous experience with another delivery device. Emerging themes included universal preference for SC administration and pain points associated with managing medication/supply orders, storing medications/supplies, troubleshooting device issues, performing burdensome medication preparations, priming tubing/needles, inserting/securing needles, programming devices, adapting to device volume constraints, and loading reservoirs or tubing into delivery devices. Conclusion: Although patients prefer LVSC administration at home compared to the alternatives, the current SCIg use process presents a variety of challenges. While not all of these factors will apply to every LVSC scenario, these insights, along with their corresponding implications for device design, provide a framework to inform user needs for LVSC self-administration, anticipate obstacles during development of new LVSC therapies, and improve existing delivery devices.
- Open Access
- 27 May 2022
- Published by Taylor & Francis in Expert Opinion on Drug Delivery
- Vol. 19 (6) , 733-742
The current paradigm for biologic initiation: a confirmatory quantitative analysis of self-injection training practices
Self-injected biologic therapies have gained significant prevalence across numerous therapeutic areas. A lack of specific guidance on best practices may lead to inadequate biologic initiation and t...
- 27 May 2022
- Published by Taylor & Francis in Expert Opinion on Drug Delivery
- Vol. 19 (6) , 733-742
Open AccessThe current paradigm for biologic initiation: a confirmatory quantitative analysis of self-injection training practices
Self-injected biologic therapies have gained significant prevalence across numerous therapeutic areas. A lack of specific guidance on best practices may lead to inadequate biologic initiation and t...
- Open Access
- 8 June 2021
- Published by Taylor & Francis in Expert Opinion on Drug Delivery
- Vol. 18 (8) , 1151-1168
The current paradigm for biologic initiation: a mixed-methods exploration of practices, unmet needs, and innovation opportunities in self-injection training
Self-injection, particularly of biologics, has become a mainstay of chronic disease management. Despite labeling requirement for healthcare provider (HCP) training, current injection initiation exp...
- 8 June 2021
- Published by Taylor & Francis in Expert Opinion on Drug Delivery
- Vol. 18 (8) , 1151-1168
Open AccessThe current paradigm for biologic initiation: a mixed-methods exploration of practices, unmet needs, and innovation opportunities in self-injection training
Self-injection, particularly of biologics, has become a mainstay of chronic disease management. Despite labeling requirement for healthcare provider (HCP) training, current injection initiation exp...
- 15 February 2019
- Published by Taylor & Francis in Expert Opinion on Drug Delivery
- Vol. 16 (3) , 187-198
The burden of at-home preparation of lyophilized parenteral medications: an analysis of contributing factors and implications for chronic disease patients and caregivers
Background: In the acute care setting, parenteral medication errors are well-studied. However, there is comparatively little research on how these issues translate to patient- or caregiver-prepared medications in the home, particularly with reconstituted medications. Methods: This was an ethnographic study designed to identify issues associated with four reconstitution use scenarios. Burden was determined by measuring the time and manipulations required to prepare reconstituted medications across three preparation phases (assembly, reconstitution, and transfer). Deviations from product instructions for use, sterility breaches, self-reported preparation complications, and supply storage conditions were also analyzed. Results: A total of 14 participants completed the study. Overall, preparation burden was markedly higher when purpose-built reconstitution devices were not available. The majority of participants reported experiencing at least one complication associated with their medication preparation process; the reconstitution phase was the most significant source of both instructions for use deviations and breaches in sterility. Participants reported that the volume and variety of medication preparation supplies were a significant source of burden. Conclusions: At-home preparation of reconstituted medications poses several challenges for patients and caregivers. As parenteral medications continue to shift towards self-administration, manufacturers should carefully consider the usability of such products and employ purpose-built reconstitution devices whenever possible.
- 15 February 2019
- Published by Taylor & Francis in Expert Opinion on Drug Delivery
- Vol. 16 (3) , 187-198
The burden of at-home preparation of lyophilized parenteral medications: an analysis of contributing factors and implications for chronic disease patients and caregivers
Background: In the acute care setting, parenteral medication errors are well-studied. However, there is comparatively little research on how these issues translate to patient- or caregiver-prepared medications in the home, particularly with reconstituted medications. Methods: This was an ethnographic study designed to identify issues associated with four reconstitution use scenarios. Burden was determined by measuring the time and manipulations required to prepare reconstituted medications across three preparation phases (assembly, reconstitution, and transfer). Deviations from product instructions for use, sterility breaches, self-reported preparation complications, and supply storage conditions were also analyzed. Results: A total of 14 participants completed the study. Overall, preparation burden was markedly higher when purpose-built reconstitution devices were not available. The majority of participants reported experiencing at least one complication associated with their medication preparation process; the reconstitution phase was the most significant source of both instructions for use deviations and breaches in sterility. Participants reported that the volume and variety of medication preparation supplies were a significant source of burden. Conclusions: At-home preparation of reconstituted medications poses several challenges for patients and caregivers. As parenteral medications continue to shift towards self-administration, manufacturers should carefully consider the usability of such products and employ purpose-built reconstitution devices whenever possible.
- Open Access
- 22 September 2017
- Published by JMIR Publications Inc. in Iproceedings
- Vol. 3 (1) , e49
Early User Centered Insights on Voice Integrated Technologies Through Retrospective Analysis
- 22 September 2017
- Published by JMIR Publications Inc. in Iproceedings
- Vol. 3 (1) , e49
Open AccessEarly User Centered Insights on Voice Integrated Technologies Through Retrospective Analysis